CDP-Choline (Citicoline) — Supplements
Intermediate in phosphatidylcholine biosynthesis; raises brain acetylcholine and dopamine; distinct from Alpha-GPC with superior striatal dopamine release; 12 RCTs in cognitive decline.
Overview
CDP-Choline (cytidine 5'-diphosphocholine, citicoline) is an endogenous intermediate in the Kennedy pathway for phosphatidylcholine (PC) synthesis — the most abundant phospholipid in cell membranes. Unlike Alpha-GPC (which primarily donates choline directly to acetylcholine synthesis), CDP-Choline splits into cytidine and choline after oral absorption: cytidine crosses the blood-brain barrier and converts to uridine (a precursor for PC synthesis and striatal dopamine receptor membrane integrity), while choline supports acetylcholine production. This dual cytidine + choline delivery gives CDP-Choline a mechanistic profile distinct from Alpha-GPC — CDP-Choline is particularly effective for dopaminergic support and is the preferred form in stroke rehabilitation and Parkinson's disease research. A Cochrane meta-analysis of 14 RCTs (n=1,051) confirmed that citicoline significantly improved memory and behavior in patients with cerebrovascular disorders. FDA has accepted two INDs for citicoline in traumatic brain injury and stroke. A 2021 multicenter double-blind RCT (Cotroneo et al., n=349, 9 months) confirmed memory and attention improvement with CDP-Choline 500 mg/day in age-associated cognitive decline. CDP-Choline has also been studied for ADHD (dopamine support), cocaine addiction (dopamine receptor upregulation), and glaucoma.
Indications
- Age-associated cognitive decline and mild cognitive impairment
- Stroke recovery and vascular cognitive impairment
- Dopaminergic support — Parkinson's disease adjunctive, ADHD
- Traumatic brain injury recovery
- Glaucoma (optic nerve neuroprotection)
- Attention and executive function optimization
Mechanism of Action
Orally administered CDP-Choline releases cytidine, which converts to uridine in the liver and crosses the blood-brain barrier. Brain uridine increases PC synthesis in neuronal membranes of the striatum, supporting the structural integrity of dopamine D2 receptor membranes and improving dopaminergic signaling — the mechanism underlying CDP-Choline's effects on attention, motivation, and addiction circuitry
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| CDP-Choline (Citicoline) | 250–500 mg | Once to twice daily, morning and early afternoon | 250 mg/day is effective for cognitive maintenance; 500–1,000 mg/day for therapeutic cognitive or dopaminergic indications; most RCTs used 500 mg/day |
Evidence Grade
GRADE C
Safety & Contraindications
- Excellent safety profile — well tolerated in all clinical trials including long-term (9-month) studies
- Most common side effects: headache, insomnia if taken late in day, GI discomfort (mild)
- Mildly stimulating — avoid dosing after 2 PM to prevent sleep disruption
- No significant drug interactions identified
- Contains choline — excess choline can worsen symptoms in individuals with TMAO-related cardiovascular risk (theoretical; clinical significance unclear at supplemental doses)
- Distinct from Alpha-GPC: CDP-Choline preferred for dopaminergic/vascular indications; Alpha-GPC preferred for pure acetylcholine/GH release support